{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-010037","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2025-12-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.495923+00:00","generated_at":"2026-05-16T13:01:59.749043+00:00","sec_items":["5.08","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"confidence":"high","headline":"KALA BIO CEO Lazar sells Series AAA preferred rights; consultant hired for strategic alternatives","bullets":["Annual meeting set for Jan 30, 2026; stockholder proposals and director nominations due Dec 27, 2025.","David Lazar sold his rights to purchase Series AAA Preferred Shares (up to $4.2M) to unaffiliated AK Holdings Group Inc.","Company retains consultant, a principal of AK Holdings, to advise on identifying and consummating a strategic alternative transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-010037","json":"https://secwatch.observer/filing/0001829126-25-010037.json","markdown":"https://secwatch.observer/filing/0001829126-25-010037.md","text":"https://secwatch.observer/filing/0001829126-25-010037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000182912625010037/0001829126-25-010037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000182912625010037/kalabio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T13:01:59.749043+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}